SCHEMBL16558798

SCHEMBL16558798

O=C1CCc2cc(CO)c(O)cc21

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PBRM1 Q86U86 1/20 0.47
HSD17B1 P14061 4/20 0.46
CASP1 P29466 1/20 0.39
CASP7 P55210 1/20 0.39
HSD17B10 Q99714 1/20 0.39
MAOA P21397 1/20 0.37
MAOB P27338 1/20 0.37
PRKCI P41743 1/20 0.37
EGFR P00533 1/20 0.36
KLF10 Q13118 1/20 0.34
POLA1 P09884 4/20 0.33
PKM P14618 1/20 0.33
MEN1 O00255 1/20 0.33
MAPK1 P28482 1/20 0.33
KMT2A Q03164 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
GRM5 P41594 1/20 0.33
KDM4E B2RXH2 1/20 0.32
CASP6 P55212 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13180230 0.93 PBRM1 (0.47) PBRM1HSD17B1CASP1CASP7HSD17B10
SCHEMBL12306065 0.86 PBRM1 (0.47) PBRM1HSD17B1CASP1CASP7HSD17B10
SCHEMBL4811613 0.84 HSD17B1 (0.44) PBRM1HSD17B1CASP1CASP7HSD17B10
SCHEMBL2932814 0.80 PBRM1 (0.57) PBRM1HSD17B1CASP1CASP7HSD17B10
SCHEMBL4812130 0.78 HSD17B1 (0.62) PBRM1HSD17B1CASP1CASP7HSD17B10
SCHEMBL31511769 0.77 HSD17B1 (0.43) PBRM1HSD17B1CASP1CASP7HSD17B10
SCHEMBL29033 0.77 HSD17B1 (0.60) PBRM1HSD17B1CASP1CASP7HSD17B10
SCHEMBL16558791 0.76 PBRM1 (0.42) PBRM1HSD17B1CASP1CASP7HSD17B10
SCHEMBL4814033 0.76 HSD17B1 (0.42) PBRM1HSD17B1CASP1CASP7HSD17B10
SCHEMBL2305004 0.76 TYR (0.46) PBRM1HSD17B1MEN1KMT2ANPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160213676-A1 Substituted 2,3-dihydro-1H-inden-1-one Retinoic acid-related orphan nuclear receptor Antagonists for Treating Multiple Sclerosis XENTHERA, INC. 2016-07-28 US disclosed
US-20160213627-A1 Substituted 2,3-dihydro-1H-inden-1-one Retinoic acid-related orphan nuclear receptor Antagonists for Treating Multiple Sclerosis XENTHERA, INC. 2016-07-28 US disclosed
US-9359315-B2 Substituted 2,3-dihydro-1H-inden-1-one retinoic acid-related orphan nuclear receptor antagonists for treating multiple sclerosis ARRIEN PHARMACEUTICALS LLC (US) 2016-06-07 US disclosed
US-20150072980-A1 Substituted 2,3-dihydro-1H-inden-1-one Retinoic acid-related orphan nuclear receptor Antagonists for Treating Multiple Sclerosis XENTHERA, INC. 2015-03-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160213627-A1 Substituted 2,3-dihydro-1H-inden-1-one Retinoic acid-related orphan nuclear receptor Antagonists for Treating Multiple Sclerosis RORA, RORB, RORC PBRM1 2706/4885HSD17B1 111/4885CASP1 2215/4885
US-20150072980-A1 Substituted 2,3-dihydro-1H-inden-1-one Retinoic acid-related orphan nuclear receptor Antagonists for Treating Multiple Sclerosis RORA, RORB, RORC PBRM1 2706/4885HSD17B1 111/4885CASP1 2215/4885
US-20160213676-A1 Substituted 2,3-dihydro-1H-inden-1-one Retinoic acid-related orphan nuclear receptor Antagonists for Treating Multiple Sclerosis RORA, RORB, RORC PBRM1 2706/4885HSD17B1 111/4885CASP1 2215/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.